<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942849</url>
  </required_header>
  <id_info>
    <org_study_id>FIN-BEM-2016-04</org_study_id>
    <nct_id>NCT02942849</nct_id>
  </id_info>
  <brief_title>Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Technology</brief_title>
  <official_title>Prospective Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finox AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Finox AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-comparative, multi-centre, multi-country, observational post-authorization&#xD;
      study, to correlate predictive factors with number of oocytes in relation to the gonadotropin&#xD;
      dose administered using a new r-hFSH product (Bemfola®) for ovarian stimulation and&#xD;
      GnRH-antagonists for pituitary suppression&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, non-comparative, multi-centre, multi-country, observational&#xD;
      post-authorization study in Germany and Austria. The study will evaluate the use of&#xD;
      follitropin alfa (Bemfola®) in controlled ovarian stimulation for IVF/ICSI.&#xD;
&#xD;
      About 30 ART centres will be involved in the study. Upon site initiation, each investigator&#xD;
      site will enrol the subjects who meet the inclusion criteria.&#xD;
&#xD;
      As this is an observational study, there will be no additional treatment or diagnostic&#xD;
      procedures performed on subjects other than those of the investigators' local routine&#xD;
      clinical practice. The decision to start ART treatment and to use Bemfola® in controlled&#xD;
      ovarian hyperstimulation (COH) following a GnRH antagonist protocol will be made&#xD;
      independently by the investigators as per the ART centre's protocol, preceding patient&#xD;
      enrollment for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>34-36 hours after hCG administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antral Follicle Count (AFC)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal FSH level</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>r-hFSH dose on first and last day of stimulation</measure>
    <time_frame>Day 1 of stimulation through to maximum Day 16 of stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of FSH stimulation (with r-hFSH daily doses)</measure>
    <time_frame>Day 1 of stimulation through to maximum Day 16 of stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>r-hFSH total dose</measure>
    <time_frame>Day 1 of stimulation through to maximum Day 16 of stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of oocyte trigger (ß-hCG / GnRH agonist)</measure>
    <time_frame>At Day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes fertilized (classified as 2PN stages)</measure>
    <time_frame>Day 1,2,3 or 5 after ovum pick-up/fertilisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of 2PN cells cryopreserved</measure>
    <time_frame>Day 1,2,3 or 5 after ovum pick-up/fertilisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos transferred</measure>
    <time_frame>Day 2-5 after ovum pick-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Biochemical pregnancies (determined by serum B-hCG levels)</measure>
    <time_frame>15-20 days after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate (gestational sacs with heartbeat per total number of embryos transferred)</measure>
    <time_frame>15-20 days after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Ovarian Hyper-Stimulation Syndrome (OHSS), classified as mild, moderate and severe</measure>
    <time_frame>From Day 1 of stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ALL other Treatment-Emergent Adverse Events</measure>
    <time_frame>From Day 1 of study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of clinical pregnancies (determined by the presence of a gestational sac)</measure>
    <time_frame>35-42 days after oocyte retrieval</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1195</enrollment>
  <condition>Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-hFSH</intervention_name>
    <description>As per standard clinical practice</description>
    <other_name>Bemfola</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will comprise 1800 women intending to undergo ovarian stimulation with&#xD;
        Bemfola® in order to have follicular puncture and oocyte retrieval performed as part of an&#xD;
        in vitro fertilisation cycle with or without intracytoplasmic sperm injection, for&#xD;
        reproductive purposes, and who are pituitary-suppressed with a GnRH antagonist.&#xD;
&#xD;
        About 30 Fertility centres will be involved in the study. Upon site initiation, each&#xD;
        investigator site will enrol the subjects who meet the inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subject justifying an IVF/ICSI treatment&#xD;
&#xD;
          -  Age over 18 years (inclusive) at the time of the screening visit&#xD;
&#xD;
          -  Signed informed patient consent&#xD;
&#xD;
          -  Received only Bemfola® for ovarian stimulation&#xD;
&#xD;
          -  Pituitary suppression with GnRH-antagonists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to the active substance follitropin alfa, FSH or to any of the&#xD;
             excipients&#xD;
&#xD;
          -  Tumours of the hypothalamus or pituitary gland&#xD;
&#xD;
          -  Ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome&#xD;
&#xD;
          -  Gynaecological haemorrhages of unknown aetiology&#xD;
&#xD;
          -  Ovarian, uterine or mammary carcinoma&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Steffen Krüssel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiter universitäres interdisziplinäres Kinderwunschzentrum Düsseldorf (UniKiD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Team Kinderwunsch Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bemfola</keyword>
  <keyword>r-hFSH</keyword>
  <keyword>Oocytes</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>OHSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

